Not recruitingEUCTR 2010-023992-24
International randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate
This historical record does not confirm current site availability.
Historical research recordMultiple countriesBipolarity
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Belgium · Germany and 2 more locations
- Study phase
- Phase 3 / Phase 4This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 88
- Sponsor
- University of Leipzig
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3, Phase 4This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Belgium, Germany, Hungary, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2010-023992-24
- Official title
Show the full official title
International randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Belgium · Germany · Hungary
1 more locations
- Spain
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Leipzig, a university.
Is this study still recruiting?
The historical registry lists this study as not recruiting.
Want to explore more studies?
Explore studiesRelated studies
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With ...
A Long-Term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolarity type I